A study to compare giving tranexamic acid all at once versus giving it in two parts to people having brain tumour surgery to see which way works better for stopping bleeding

Comparison of the effect of tranexamic acid bolus dose with bolus followed by infusion on perioperative blood loss in adult patients undergoing brain tumour surgery - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/05/067553

Enrollment

Registered

2024-05-17

Start date

Unknown

Completion date

Unknown

Last updated

2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D332- Benign neoplasm of brain, unspecified Health Condition 2: D320- Benign neoplasm of cerebral meninges Health Condition 3: C717- Malignant neoplasm of brain stem Health Condition 4: C719- Malignant neoplasm of brain, unspecified Health Condition 5: C716- Malignant neoplasm of cerebellum Health Condition 6: C700- Malignant neoplasm of cerebral meninges Health Condition 7: C715- Malignant neoplasm of cerebral ventricle Health Condition 8: C711- Malignant neoplasm of frontal

Interventions

Intervention1: Tranexamic Acid: Injection Tranexamic Acid 15 mg/kg upto 1 gram over 20 mins as bolus Control Intervention1: Tranexamic Acid: Injection Tranexamic Acid 15 mg/kg upto 1 gram bolus dose f

Eligibility

Inclusion criteria

Inclusion criteria: 1. Adult patients aged 18 to 65 years undergoing brain tumour surgery 2. American Society of Anaesthesiologists (ASA) grade I and II only

Exclusion criteria

Exclusion criteria: 1. Patients who have a history of allergic reaction to tranexamic acid 2. Patients having previous documented history of thromboembolic disease 3. Patients who have documented coagulopathies diagnosed before surgery 4. Patients with documented hepatic or renal dysfunction

Design outcomes

Primary

Measure	Time frame
The amount of blood loss during surgery in millilitres Timepoint: At the end of surgery i.e. skin closure has finished	—

Secondary

Measure	Time frame
Blood loss during surgery Timepoint: Every hourly starting from time of incision till completion of surgery i.e. skin closure completed	—

Countries

India

Contacts

Public ContactUtkarsh Rathi

VMMC and Safdarjung Hospital New Delhi

drmkumath@gmail.com9810310159

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026